Significant reduction in risk regarding CRC was found for those taking selective COX-2 inhibitors over 6 months (28%, OR = 0.72), 1 year (40%, OR = 0.60), 3 years (42%, OR = 0.58) and 5 years (49%, OR = 0.51). Here, PTGS2 is linked to colorectal carcinoma.